First Results From CC-92480-MM-002: A Phase 1/2 Study Of The Potent, Novel CELMoD Agent CC-92480, In Combination With Dexamethasone And Bortezomib In Patients With Relapsed/Refractory Multiple Myeloma
Por:
Richardson, PG, Ocio, EM, Raje, N, Gregory, T, White, D, Oriol, A, Sandhu, I, Raab, MS, LeBlanc, R, Valdes, CR, Trudel, S, Wasch, R, Perrot, A, Bahlis, NJ, Zhou, ZH, Lamba, M, Amatangelo, M, Civardi, T, Katz, J, Maciag, P, Peluso, T and Dimopoulos, MA
Publicada:
1 abr 2022
Resumen:
Filiaciones:
Richardson, PG:
Dana Farber Canc Inst, Boston, MA 02115 USA
Ocio, EM:
Hosp Univ Marques De Valdecilla IDIVAL, Santander, Spain
Raje, N:
Massachusetts Gen Hosp, Boston, MA 02114 USA
Gregory, T:
Colorado Blood Canc Inst, Denver, CO USA
White, D:
Dalhousie Univ, Halifax, NS, Canada
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
:
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
Sandhu, I:
Univ Alberta, Edmonton, AB, Canada
Raab, MS:
Univ Klinikum Heidelberg, Heidelberg, Germany
LeBlanc, R:
Hop Maison Neuve Rosemont, Montreal, PQ, Canada
Valdes, CR:
Wake Forest Baptist Hlth, Winston Salem, NC USA
Trudel, S:
Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
Wasch, R:
Univ Klinikum Freiburg, Freiburg, Germany
Perrot, A:
Inst Univ Canc Toulouse Oncopole, Toulouse, France
Bahlis, NJ:
Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
Zhou, ZH:
Bristol Myers Squibb, Princeton, NJ USA
Lamba, M:
Bristol Myers Squibb, Princeton, NJ USA
Amatangelo, M:
Bristol Myers Squibb, Princeton, NJ USA
Civardi, T:
Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
Katz, J:
Bristol Myers Squibb, Princeton, NJ USA
Maciag, P:
Bristol Myers Squibb, Princeton, NJ USA
Peluso, T:
Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
Dimopoulos, MA:
Alexandra Gen Hosp, Athens, Greece
|